Friday, December 16, 2016

BRIEF-Aptevo Therapeutics announces publication of phase 2 clinical data for Otlertuzumab

* "latest data show combination of Otlertuzumab and

bendamustine is well tolerated"

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)